新阿尔茨海默氏病的药物如果被早期抓住,可能会减慢进展速度,但英国的国民健康服务系统(NHS)缺乏广泛提供这些药物的准备。 New Alzheimer’s drugs can slow progression if caught early, but the UK’s NHS lacks readiness to deliver them widely.

新的阿尔茨海默氏症治疗方法,如多纳内马布和白血肿,如果早发,会减缓疾病蔓延的速度,而血液测试可以促成广泛的早期检测,这标志着与癌症护理突破相类似的重大进步。 New Alzheimer’s treatments like donanemab and lecanemab can slow disease progression if given early, and blood tests may enable widespread early detection, marking a major advance comparable to breakthroughs in cancer care. 然而,专家们警告说,联合王国的国民保健制度没有做好大规模实施这些创新的准备,由于费用问题,国家环境卫生委员会拒绝提供资金。 However, experts warn the UK’s NHS is unprepared to deliver these innovations at scale, with NICE rejecting funding due to cost concerns. 尽管有执照的药品和有前途的诊断,但基础设施、劳动力和获得机会方面的系统性差距——特别是在服务不足的地区——威胁着公平的护理。 Despite licensed drugs and promising diagnostics, systemic gaps in infrastructure, workforce, and access—especially in underserved areas—threaten equitable care. 由于痴呆症预计会影响到三分之一的今天出生的人和预计到2040年将达到140万的病例,研究人员敦促紧急改革医疗保健的提供、政策和公众支持,以确保病人能够受益于科学进步。 With dementia expected to affect one in three people born today and cases projected to reach 1.4 million by 2040, researchers urge urgent reforms in healthcare delivery, policy, and public support to ensure patients can benefit from scientific progress.